This is an interesting new @medicinespatentpool.org licence. Generic manufacturers, anywhere in the world, interested in producing baloxavir marboxil should contact the MPP through its expression of interest portal: medicinespatentpool.org/partners/how...
MPP licence agreements’ aim is to make safe, effective and affordable essential medicines available in low- and middle-income countries.
Today at #WHA79, MPP and Roche celebrated the signing of a public health-oriented voluntary licence agreement for baloxavir marboxil, an #influenza antiviral treatment recommended by @who.int.
Read the announcement: bit.ly/4wwZsW1
@unitaid.bsky.social @drduneton.bsky.social
The Medicines Patent Pool (MPP) and Roche have signed a voluntary licence agreement to expand access to baloxavir marboxil (Xofluza®), an innovative antiviral treatment for influenza recommended by th...
